Toronto-based Cybin Inc. (NYSE: CYBN) (NEO: CYBN) increased its losses for its first fiscal quarter of 2023 to C$14.5 million, up from C$13.1 million a year prior, but company leadership remained bullish that it’s on the right path to gain federal approval in the U.S. for its psychedelic mental health treatments. Cybin continued investing in […]